Highlights

  • Cyclopharm shares jumped 13.33% to AUD 0.85 on 31 March 2026, following a major expansion update in the United States.
  • The Company’s US footprint now includes 50 revenue-generating installations linked to 331 contracted locations.
  • Technegas has secured adoption in six of the Top 20 US hospitals, including Mass General Brigham and UNC Health.
  • Strategic penetration into the Veterans Affairs (VA) network continues with the fifth hospital installation now confirmed.
  • Inclusion as a "preferred agent" in upcoming international clinical guidelines is expected to accelerate adoption from late May 2026.

Cyclopharm Limited (ASX:CYC) shares surged 13.33% to AUD 0.85 during the afternoon session on 31 March 2026. The rally follows a comprehensive update detailing accelerating commercial momentum for its flagship Technegas technology in the United States. The Company reported a rapid expansion across high-profile academic health systems and government-run medical centers, signaling a successful transition from early market entry to a scaled institutional penetration phase.

Scaled Institutional Adoption and Network Expansion

Cyclopharm is increasingly leveraging its "lighthouse" sites—premier medical institutions—to trigger wider network adoption. A key milestone reported today is the installation of a second Technegas system at Brigham and Women’s Hospital, part of the Mass General Brigham (MGB) network. This marks the sixth "Top 20" US hospital to implement the technology.

Other significant network wins include:

  • UNC Health: Installation of the first system completed, with a second scheduled shortly.
  • Emory Health Care: Progressing toward its fourth installation, reflecting deep internal utilization growth.
  • Stony Brook University Health System: Secured a contract for two installations in Long Island, New York, a critical regional market.
  • MUSC (South Carolina): Signed a commercial contract for an initial two sites with the potential for five total locations.

Strategic Gains in Government and VA Channels

The Company continues to make inroads into the Veterans Affairs (VA) and military hospital sectors, which provide highly credible and scalable deployment pathways. The Joseph Maxwell Cleland Atlanta VA Medical Center recently issued a purchase order, representing the fifth VA hospital to adopt the Technegas system. Management noted that additional military facilities are currently moving through the procurement and approval stages.

Robust Commercial Pipeline

As of 31 March 2026, Cyclopharm has engaged with approximately one-quarter of the 5,139 US sites that perform nuclear medicine lung imaging. The current pipeline demonstrates a massive scale of opportunity:

  • Current Footprint: 50 active installations linked to 331 secondary contracted locations.
  • Active Contracting: 74 primary installations are currently in the installation or contracting phase.
  • Early-Stage Engagement: Over 640 sites are at the initial proposal stage, representing the next wave of potential growth.

Clinical Validation: A Late-May Catalyst

A significant upcoming catalyst for the Company is the finalization of new US and international clinical guidelines for ventilation-perfusion (V/Q) imaging. Technegas has already been recognized as a "preferred ventilation imaging agent" in the draft guidelines developed by global nuclear medicine bodies.

These guidelines are expected to be finalized at the SNMMI annual meeting in late May 2026. Because these publications dictate physician practice and hospital reimbursement decisions, Cyclopharm anticipates that formal publication will further accelerate the clinical adoption and institutional uptake of Technegas across the US market.

Investor Takeaway

Cyclopharm (ASX:CYC) appears to have reached a critical "inflection point" in its US expansion strategy. By successfully moving from individual site sales to large-scale integrated healthcare network contracts (like MGB and UNC Health), the Company is establishing a more repeatable and scalable growth model.

The 13.33% share price increase reflects investor confidence in both the current installation rate and the looming regulatory/clinical tailwinds expected in May. With 25% of the total US market already engaged and a preferred status in upcoming global guidelines, Cyclopharm is well-positioned to convert its massive pipeline into long-term, recurring revenue.